Full Press Release Details
Cerus Corporation Reports Fourth Quarter and Year-End 2010 Results
CONCORD, CA, March 3,
2011 - Cerus Corporation (NASDAQ: CERS) today announced financial results for the fourth quarter and year ended December 31, 2010.
revenue for the year ended December 31, 2010 was $23.1 million, an increase of $5.1 million, or 29%, from the same period in 2009. Product revenue for 2010 was $21.7 million, up 29% from the prior year. Government grant revenue for work
performed under contract with the United States Department of Defense totaled $1.4 million in 2010, up from the $1.2 million recognized in 2009. Total revenue for the fourth quarter of 2010 was $6.5 million, up from $5.5 million during the
fourth quarter of 2009. Government grant revenue recognized in the fourth quarter of 2010 was $0.5 million, compared to $0.2 million recognized during the fourth quarter of 2009.
2010 represented our fifth straight year of top-line growth, with revenue growing 29% year over year. said Claes Glassell, President and Chief Executive Officer of Cerus Corporation.
Looking forward, we believe economic headwinds and prolonged adoption decisions will impact our growth rate in the near term, and conservatively anticipate 2011 revenue growth of 20%.
Gross margins for the year ended December 31, 2010 were 48%, compared to 30% during the same period of 2009. Gross margins for the fourth quarter of
2010 were 44%, compared to 32% during the same period in 2009. The improvement in gross margins is attributable to lower per-unit costs associated with INTERCEPT Blood System product sold in 2010 compared to 2009.
Total operating expenses for the year ended December 31, 2010 were $27.0 million, compared to $29.2 million during the same period in 2009.
Operating expenses during the fourth quarter of 2010 were $7.6 million, compared to $6.7 million during the same period of 2009. During the fourth quarter of 2010, Cerus recorded $0.2 million of one-time net costs related to the acquisition of
certain BioOne assets. During the same period in 2009, Cerus recorded non-cash impairment charges of $1.5 million related to its equity ownership in BioOne.
Net loss for 2010 was $16.9 million, or $0.42 per share, compared to $24.1 million, or $0.69 per share, for 2009. Net loss for the fourth quarter of 2010 was $2.6 million, or $0.06 per share, compared to
a net loss of $4.9 million, or $0.13 per share, for the same period of 2009.
At December 31, 2010, Cerus had cash, cash equivalents and short-term investments of $30.0 million, up
from $19.9 million at December 31, 2009. During the fourth quarter of 2010, Cerus completed a public offering resulting in aggregate gross proceeds to Cerus of approximately $21.0 million. Cerus recently entered into an amendment with its
lender to extend the availability of the second $5.0 million under its growth capital facility to September 30, 2011.
QUARTERLY CONFERENCE CALL
host a conference call and webcast at 4:15 p.m. Eastern time today to discuss its financial results and provide a general business overview. To access the live webcast, please visit the Investor Relations page of the Cerus website at
http://investor.cerus.com. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).
A replay will be available on Cerus website, or by dialing 800-642-1687 (U.S.) or 706-645-9291 (international) and entering conference ID number 47634450. The replay will be available approximately
three hours after the call through March 31, 2011.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate both
established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in Europe, the CIS, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to Cerus expectations regarding its 2011 revenue growth rate. These forward-looking statements are based upon the company s current expectations. Actual results could differ materially
from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, accounting practices, foreign exchange rates, risks and uncertainties
associated with Cerus business and finances in general, as well as other risks detailed in the Cerus
filings with, the Securities and Exchange Commission (SEC), including in Cerus quarterly report on Form 10-Q for the quarter ended September 30, 2010, filed with the SEC on
November 15, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a
result of new information, future events, changed assumptions or otherwise.
Financial Tables Attached
CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATION
(In thousands except per share information)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 5,965 | $ | 5,228 | $ | 21,677 | $ | 16,751 | ||||||||
| Government grant and cooperative agreements | 496 | 246 | 1,432 | 1,231 | ||||||||||||
| Total Revenue | 6,461 | 5,474 | 23,109 | 17,982 | ||||||||||||
| Cost of product revenue | 3,630 | 3,724 | 12,046 | 12,580 | ||||||||||||
| Gross profit | 2,831 | 1,750 | 11,063 | 5,402 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 1,419 | 1,505 | 5,195 | 6,372 | ||||||||||||
| Selling, general and administrative | 5,913 | 5,017 | 21,577 | 21,867 | ||||||||||||
| Amortization of intangible assets | 67 | 67 | ||||||||||||||
| Restructuring | (15 | ) | 841 | |||||||||||||
| Acquisition related costs and impairment of long-term investment, net | 182 | 1,536 | 182 | 1,536 | ||||||||||||
| Gain on settlement | (1,381 | ) | (1,381 | ) | ||||||||||||
| Total operating expenses | 7,581 | 6,662 | 27,021 | 29,235 | ||||||||||||
| Loss from operations | (4,750 | ) | (4,912 | ) | (15,958 | ) | (23,833 | ) | ||||||||
| Interest and other income (expense), net | 2,120 | 23 | (953 | ) | (302 | ) | ||||||||||
| Net loss | $ | (2,630 | ) | $ | (4,889 | ) | $ | (16,911 | ) | $ | (24,135 | ) | ||||
| Net loss per share basic and diluted | $ | (0.06 | ) | $ | (0.13 | ) | $ | (0.42 | ) | $ | (0.69 | ) | ||||
| Weighted average common shares outstanding used for basic and diluted loss per share | ||||||||||||||||
| Basic | 44,040 | 38,680 | 40,300 | 34,750 | ||||||||||||
| Diluted | 44,040 | 38,680 | 40,300 | 34,750 |
Condensed Consolidated Unaudited Balance Sheets
| December 31, 2010 | December 31, 2009 | |||||||
| Cash, cash equivalents, and short-term investments | $ | 30,009 | $ | 19,931 | ||||
| Accounts receivable and other current assets | 5,789 | 4,721 | ||||||
| Inventories | 5,957 | 7,707 | ||||||
| Property and equipment, net | 2,390 | 1,217 | ||||||
| Purchased intangible assets and goodwill | 3,266 | |||||||
| Other assets | 756 | 915 | ||||||
| Total Assets | $ | 48,167 | $ | 34,491 | ||||
| Accounts payable and accrued liabilities | $ | 8,982 | $ | 9,718 | ||||
| Accrued restructuring | 113 | |||||||
| Deferred revenue | 509 | 345 | ||||||
| Long-term debt, current | 1,747 | |||||||
| Warrant liability | 8,465 | 2,737 | ||||||
| Long-term debt, non-current | 3,131 | |||||||
| Other long-term liabilities | 1,601 | 130 | ||||||
| Total liabilities | 24,435 | 13,043 | ||||||
| Stockholders equity | 23,732 | 21,448 | ||||||
| Total liabilities and stockholders equity | $ | 48,167 | $ | 34,491 |